MML Investors Services LLC Has $4.72 Million Stock Position in argenx SE (NASDAQ:ARGX)

MML Investors Services LLC boosted its holdings in shares of argenx SE (NASDAQ:ARGX) by 16.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,699 shares of the company’s stock after acquiring an additional 1,255 shares during the quarter. MML Investors Services LLC’s holdings in argenx were worth $4,715,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Blue Trust Inc. lifted its position in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. Cromwell Holdings LLC increased its stake in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC lifted its position in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of argenx during the 2nd quarter valued at $76,000. Finally, Keudell Morrison Wealth Management purchased a new position in shares of argenx during the 3rd quarter valued at $207,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Up 0.6 %

Shares of NASDAQ:ARGX opened at $607.21 on Friday. The company has a market cap of $36.66 billion, a price-to-earnings ratio of -690.01 and a beta of 0.59. The business has a 50 day moving average price of $581.03 and a 200 day moving average price of $513.48. argenx SE has a twelve month low of $327.73 and a twelve month high of $630.00.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the business earned ($1.25) earnings per share. Analysts anticipate that argenx SE will post 2.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ARGX shares. Oppenheimer reissued an “outperform” rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and set a $617.00 price target on shares of argenx in a report on Wednesday, November 20th. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective on the stock in a research report on Tuesday, November 12th. Finally, Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $635.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.